CA2461714C - Treatment of chronic joint inflammation - Google Patents

Treatment of chronic joint inflammation Download PDF

Info

Publication number
CA2461714C
CA2461714C CA2461714A CA2461714A CA2461714C CA 2461714 C CA2461714 C CA 2461714C CA 2461714 A CA2461714 A CA 2461714A CA 2461714 A CA2461714 A CA 2461714A CA 2461714 C CA2461714 C CA 2461714C
Authority
CA
Canada
Prior art keywords
antibody
ser
gly
thr
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2461714A
Other languages
English (en)
French (fr)
Other versions
CA2461714A1 (en
Inventor
John Isaacs
Herman Waldmann
Geoffrey Hale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9922741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2461714(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of CA2461714A1 publication Critical patent/CA2461714A1/en
Application granted granted Critical
Publication of CA2461714C publication Critical patent/CA2461714C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2461714A 2001-09-26 2002-09-26 Treatment of chronic joint inflammation Expired - Fee Related CA2461714C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0123156.2 2001-09-26
GB0123156A GB2380127A (en) 2001-09-26 2001-09-26 Treatment of chronic joint inflammation
PCT/GB2002/004358 WO2003026692A2 (en) 2001-09-26 2002-09-26 Treatment of chronic joint inflammation using an antibody against the cd3 antigen complex

Publications (2)

Publication Number Publication Date
CA2461714A1 CA2461714A1 (en) 2003-04-03
CA2461714C true CA2461714C (en) 2013-03-12

Family

ID=9922741

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2461714A Expired - Fee Related CA2461714C (en) 2001-09-26 2002-09-26 Treatment of chronic joint inflammation

Country Status (10)

Country Link
US (1) US20050037004A1 (enExample)
EP (3) EP1803466B1 (enExample)
JP (1) JP4694784B2 (enExample)
AU (2) AU2002329423B2 (enExample)
CA (1) CA2461714C (enExample)
DE (1) DE60217698T2 (enExample)
ES (2) ES2279884T3 (enExample)
GB (1) GB2380127A (enExample)
PT (1) PT1432445E (enExample)
WO (1) WO2003026692A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US6660948B2 (en) * 2001-02-28 2003-12-09 Vip Investments Ltd. Switch matrix
MY154009A (en) 2002-03-13 2015-04-30 Biogen Idec Inc Anti-alpha v beta 6 antibodies
EP1664116A4 (en) * 2003-08-22 2009-06-03 Biogen Idec Inc IMPROVED ANTIBODIES WITH CHANGED EFFECTOR FUNCTION AND MANUFACTURING METHOD THEREFOR
EP2397189B1 (en) 2003-11-14 2015-03-18 Brigham and Women's Hospital, Inc. Methods of modulating immunity
PT1737490E (pt) * 2004-04-06 2010-08-31 Novimmune Sa Processos de tratamento da aterosclerose
US7728114B2 (en) 2004-06-03 2010-06-01 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
RU2271816C1 (ru) * 2004-07-08 2006-03-20 Григорий Менделевич Дубровин Способ профилактики посттравматического остеоартроза
AU2005287406B2 (en) 2004-07-26 2011-08-18 Biogen Ma Inc. Anti-CD154 antibodies
US8329186B2 (en) 2004-12-20 2012-12-11 Isu Abxis Co., Ltd Treatment of inflammation using BST2 inhibitor
US7740856B2 (en) 2005-12-20 2010-06-22 Isu Abxis Co., Ltd. Effect of BST2 on inflammation
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
WO2007009064A2 (en) 2005-07-11 2007-01-18 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
WO2007117600A2 (en) * 2006-04-07 2007-10-18 Macrogenics, Inc. Combination therapy for treating autoimmune diseases
WO2007147090A2 (en) * 2006-06-14 2007-12-21 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
SG173364A1 (en) 2006-07-10 2011-08-29 Biogen Idec Inc Compositions and methods for inhibiting growth of smad4-deficient cancers
EP2170951A2 (en) * 2007-05-31 2010-04-07 Genmab A/S Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering
WO2010132872A1 (en) * 2009-05-15 2010-11-18 Novimmune S.A Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists
CA2778334A1 (en) * 2009-10-20 2011-04-28 Charlotte Mckee Anti-cd3 antibody dosing in autoimmune disease
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US20220372148A1 (en) 2019-07-05 2022-11-24 Ono Pharmaceutical Co., Ltd. A pharmaceutical composition for treating hematological cancer
US12122850B2 (en) 2022-03-14 2024-10-22 LamKap Bio gamma AG Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183657A (en) 1988-03-11 1993-02-02 Celltech Limited Antibodies for use in antilymphocyte antibody therapy
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
DK0610447T3 (da) 1991-10-15 1999-08-23 Btg Int Ltd CDw52-specifikt antistof til behandling af T-cellemedieret inflammation af leddene
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
SE510197C2 (sv) 1997-02-06 1999-04-26 Asea Brown Boveri Förfarande och anordning för styrning av ett kondensatordon för en shuntkopplad statisk kompensatorenhet med deblockeringssignaler för indikering av icke strömförande tillstånd hos ingående ventiler
US5843597A (en) * 1997-12-01 1998-12-01 Eveready Battery Company, Inc. Ribbed gasket for miniature galvanic cell
CA2224256C (en) * 1997-12-09 2013-04-30 I.N.S.E.R.M. Method for treating established spontaneous auto-immune diseases in mammals
GB9815909D0 (en) * 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
AUPQ431299A0 (en) * 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance

Also Published As

Publication number Publication date
DE60217698T2 (de) 2007-10-25
GB0123156D0 (en) 2001-11-21
US20050037004A1 (en) 2005-02-17
EP2199307B1 (en) 2014-11-05
DE60217698D1 (de) 2007-03-08
EP1803466B1 (en) 2012-07-11
GB2380127A (en) 2003-04-02
PT1432445E (pt) 2007-03-30
ES2389781T3 (es) 2012-10-31
EP1803466A1 (en) 2007-07-04
EP2199307A1 (en) 2010-06-23
JP2005506331A (ja) 2005-03-03
WO2003026692A2 (en) 2003-04-03
WO2003026692A3 (en) 2003-12-18
AU2008207338A1 (en) 2008-09-04
EP1432445A2 (en) 2004-06-30
AU2008207338B2 (en) 2011-12-08
EP1432445B1 (en) 2007-01-17
AU2002329423B2 (en) 2008-05-15
CA2461714A1 (en) 2003-04-03
ES2279884T3 (es) 2007-09-01
JP4694784B2 (ja) 2011-06-08

Similar Documents

Publication Publication Date Title
AU2008207338B2 (en) Treatment of chronic joint inflammation using an antibody against the CD3 antigen complex
AU2002329423A1 (en) Treatment of chronic joint inflammation using an antibody against the CD3 antigen complex
JP4065554B2 (ja) 抗体の調製
RU2562874C1 (ru) Антитела против ох40 и способы их применения
EP2265643B1 (en) Dosing regimen for treating psoriasis and rheumatoid arthritis
JP4448906B2 (ja) Ｃｄ４特異的抗体ｔｒｘ１およびその使用
CN102027016A (zh) 一种治疗疾病的试剂
CN114630678A (zh) FcRn抗体及其使用方法
JP2006519228A (ja) 抗原に対し霊長類を免疫寛容化する組成物と方法
US12492231B2 (en) Multimeric hybrid Fc proteins for replacement of IVIG
CN117843789A (zh) 治疗性抗cd40配体抗体
JP2008503593A (ja) 霊長類で寛容を誘導するための抗ｃｄ４抗体で最適化された投薬
JP2012504110A (ja) 疾患治療組成物
CN116262790A (zh) 嵌合的抗cd27抗体组合物及其应用
GB2376466A (en) TRX1 antibody
EA050428B1 (ru) АНТИТЕЛА ПРОТИВ FcRn И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170926